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Background: StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe
adverse drug reactions with high mortality.
Methods: To present the clinical characteristics of SJS and TEN in Japan and evaluate the efﬁcacy of
treatments, we retrospectively analyzed cases of SJS and TEN treated in 2 university hospitals during
2000e2013.
Results: Fifty-two cases of SJS (21 males and 31 females; average age, 55.1 years) and 35 cases of TEN (17
males and 18 females; average age, 56.6 years) were included in this study. Twenty-eight cases of SJS
(53.8%) and all cases of TEN were caused by drugs. Hepatitis was the most common organ involvement in
both SJS and TEN. Renal dysfunction, intestinal disorder, and respiratory disorder were also involved in
some cases. The major complication was pneumonia and sepsis. All cases except for 3 cases were treated
systemically with corticosteroids. Steroid pulse therapy was performed in 88.6% of TEN. Plasmapheresis
and/or immunoglobulin therapy was combined with steroid therapy mainly in TEN after 2007. The
mortality rate was 6.9% and the rates for SJS and TEN were 1.9% and 14.3%, respectively. These were much
lower than predicted mortality according to a severity-of-illness scoring system for TEN prognosis
(SCORTEN) score. When comparing the mortality rate between 2000e2006 and 2007e2013, it was
decreased from 4.5% to 0.0% in SJS and from 22.2% to 5.3% in TEN.
Conclusions: Treatment with steroid pulse therapy in combination with plasmapheresis and/or immu-
noglobulin therapy seems to have contributed to prognostic improvement in SJS/TEN.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ental Immuno-Dermatology,
e, 3-9 Fukuura, Kanazawa-ku,
mane).
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StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) are potentially fatal disorders, characterized by high fever,
wide-spread blistering exanthema of macules, and atypical target-
like lesions, accompanied bymucosal involvement.1e3 Both of these
disorders are often accompanied by complications in numerousvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Y. Yamane et al. / Allergology International 65 (2016) 74e81 75organs, such as liver, kidney, and lung, which make treatment
difﬁcult and sometimes determine the length of convalescence.
They are considered to be diseases on the same spectrum but with
different severities.4,5 In SJS, the less severe of the 2 conditions,
detachment of the epidermis occurs on less than 10% of the body
surface area. The area of epidermal detachment is wider in TEN, and
this disorder is often accompanied by more complications in more
organs than are found in SJS.
The treatment for these diseases is not well established. In
addition to supportive care, systemic corticosteroids,6,7 high-dose
intravenous immunoglobulin (IVIG),8e11 and plasmapheresis12e14
have been used and considered effective in many reports. How-
ever, the effects of these therapies are still controversial.15 In
Japan, treatment with systemic corticosteroid has increasingly
been used, since guidelines for the management of SJS and TEN
were established in 2007 and revised in 2009 by the Japanese
Research Committee on Severe Cutaneous Adverse Reaction (J-
SCAR) supported by the Ministry of Health, Labour, and Welfare
of Japan.16 Under these guidelines, systemic corticosteroids are
regarded as the ﬁrst line of treatment and, in severe cases, steroid
pulse therapy is recommended. IVIG and plasmapheresis are
considered as additional modalities for use with systemic corti-
costeroids. After plasmapheresis for SJS/TEN became eligible for
coverage by health insurance in Japan in 2006, use of plasma-
pheresis in the treatment of SJS/TEN has been increasing, espe-
cially in intractable TEN.
The aim of this study is to present the clinical characteristics of
SJS/TEN and to evaluate the current treatments. We retrospectively
analyzed cases of SJS/TEN treated in our 2 university hospitals from
2000 to 2013. The data showed low mortality with intensive
treatments, particularly in patients treated after 2007.
Methods
We collected the cases of SJS and TEN, which were treated in
Yokohama City University Hospital and Yokohama City University
Medical Center between January 2000 and December 2013. The
diagnosis of SJS/TEN was based on Bastuji-Garin criteria.3 For SJS,
symptoms should include acute conditions characterized by mu-
cous membrane erosions and skin lesions (described as macules,
atypical target-like lesions, bulla, or erosions) with a maximum
epidermal detachment of less than 10% of the total body surface
area (BSA); and for TEN the symptoms should include a maximum
epidermal detachment of more than 10% of the BSA in addition to
the symptoms above. Cases that were classiﬁed as overlap of SJS/
TEN according to the Bastuji-Garin criteria with a maximum
epidermal detachment of 10e30% of the BSA were included as TEN
in this study.
The following data were collected: Demographic information
(age and sex), relevant past medical history and coexisting condi-
tions, antecedent use of medications, time between the ﬁrst caus-
ative drug intake and the onset of symptoms, maximum epidermal
detachment as a percentage of BSA, presence and extent of mucous
membrane involvement, laboratory data, results of patch testing
and lymphocyte stimulation tests using suspected drugs, organ
involvement and complications, treatments including corticoste-
roid therapy, intravenous immunoglobulin therapy (IVIG), and
plasmapheresis, and mortality. Causative drugs were determined
by considering the history of drug administration and the results of
patch testing and lymphocyte stimulation tests if performed.
To evaluate the efﬁcacy of treatments, SCORTEN, a severity-of-
illness scoring system for TEN prognosis was used. SCORTEN,
which consists of 7 clinical values, was advocated by Bastuji-Garin S
et al. in 2000 and is nowwidely accepted as the standard prognostic
tool for the prediction of mortality in patients with TEN and SJS.17The SCORTEN criteria are: serum blood urea nitrogen >10 mmol/
L, serum bicarbonate <20 mmol/L, serum glucose >14 mmol/L, age
40 years, malignancy present, heart rate 120 bpm, and per-
centage of BSA with epidermal detachment 10%. The mortality
rate was predicted according to the SCORTEN total score as follows:
0e1 points, 3.2%; 2 points, 12.1%; 3 points, 35.3%; 4 points, 58.3%;
and 5 or more points, 90%.
Results
Age and sex (Fig. 1)
Eighty-seven cases including 52 of SJS and 35 of TEN were
treated during the 14 years of the study period and all of themwere
analyzed in this study. Patients with SJS, comprising 21 males and
31 females, were aged between 17 and 87 years (average, 55.1
years). Patients with TEN, comprising 17 males and 18 females,
were aged between 2 and 80 years (average, 56.6 years). Average
ages were not different between SJS and TEN, but peaks were noted
of patients aged in their 40s and 70s in SJS and of patients in their
70s in TEN.
Interval between the ﬁrst drug intake and onset of symptoms (Fig. 2)
The intervals between the ﬁrst drug intake and the onset of
symptoms of 41 cases of SJS and 24 cases of TEN are shown in Fig. 2.
The average intervals were 18.0 days in SJS and 11.7 days in TEN. In
TEN, symptoms usually developed within 7 days of ﬁrst drug
intake; TEN thus seemed to develop earlier after drug intake than
did SJS.
Total number of days of the hospital stay (Fig. 3)
The total number of days of the hospital stay was counted to
evaluate the period in which care was required for SJS/TEN. All
patients, except 2 patients with SJS whose symptoms were mild,
were hospitalized for treatments. In cases that developed SJS/TEN
during treatment of coexisting disorders in hospital, the total
number of days of the hospital staywas counted from the day of the
ﬁrst consult with dermatologists to the day of nearly recovered
condition.
The average numbers of days of the hospital stay were 20.8 days
in SJS and 34.1 days in TEN. One patient with SJS was hospitalized
for 77 days with Cytomegalovirus infection, Aspergillus pneumonia,
and acute hepatitis due to antifungal drugs. TEN patients whowere
discharged within 14 days included 2 deceased cases. Except for
those cases, 1 case was transferred to another hospital because of a
coexisting psychological disorder and another case was enrolled to
the cardiovascular medicine department because of severe mitral
stenosis. Only a 35-year-old man with overlap of SJS/TEN left the
hospital in 13 days. He had no complications except mild hepatitis
and was treated with corticosteroids alone. He recovered imme-
diately without developing any complications after he was
admitted to the hospital.
Causes of SJS and TEN
In SJS, 28 cases (53.8%) were considered to be caused by an
adverse reaction to drugs, and 8 cases (15.4%) were suspected to be
caused by infection, including 3 cases of Mycoplasma pneumonia.
The causes of the other cases were not determined. In contrast, all
TEN cases were suspected to be caused by an adverse reaction to
drugs. Causative drugs of SJS and TEN are listed in Table 1. In
agreement with past reports, antibiotics, nonsteroidal anti-
inﬂammatory drugs (NSAIDs), cold medicines, and anticonvulsants
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Fig. 1. Ages of patients with SJS and TEN. Fifty-two cases of SJS and 35 cases of TEN were included in this study.
Y. Yamane et al. / Allergology International 65 (2016) 74e8176were the major causative drugs. However, it is noteworthy that
anticonvulsants were remarkably frequent as causative drugs in SJS.
Skin and mucocutaneous lesions
The degree of maximum epidermal detachment in TEN varied
widely. The range was 10%e100% of BSA and the average was 44.7%
of BSA. One-third of TEN patients showed a maximum epidermal
detachment of more than 50% of BSA and 5 cases (14.3%) showed a
maximum epidermal detachment of more than 90% of BSA.
As for the mucocutaneous lesions, keratoconjunctivitis was
observed in 39 cases (75.0%) of SJS and 17 cases (48.6%) of TEN.
Keratoconjunctivitis included clinical features such as conjunctival
injection and erosion of the keratoconjunctiva, pseudomembrane
of the conjunctiva, and eye mucus. Painful labial and oral erosions
were observed in 50 cases (96.2%) of SJS and 19 cases (54.3%) of
TEN. Genital problems, found mainly by pain during urination,
were observed in 19 cases (36.5%) of SJS and 17 cases (48.6%) of TEN.C
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Fig. 2. Time between the ﬁrst causative drug intake and the onset of symptoms. Forty-one c
SJS and 11.7 days in TEN.Organ involvement and complications
Organ involvement and other complications commonly
accompanied both SJS and TEN (Table 2), and were found more
frequently in TEN. Hepatitis was the most common complication in
SJS (26 cases, 50%) and TEN (15 cases, 42.9%). Renal dysfunction (5
cases, 9.6%) and gastro-intestinal disorder (5 cases, 9.6%) followed
liver dysfunction in SJS. As for TEN, renal dysfunction and gastro-
intestinal disorder were observed in 8 cases (22.9%) and 4 cases
(11.4%), respectively. One TEN case with severe renal dysfunction
received hemodialysis. Encephalopathy was sometimes associated
with SJS and TEN. It was observed at a higher frequency (5 cases,
14.3%) in TEN than in SJS (2 cases, 3.8%). One case developed
convulsion and the others manifested decreased levels of con-
sciousness without accompaniment by cerebrovascular disorder.
Infections such as pneumonia and sepsis were the main com-
plications both in SJS and TEN. Especially in TEN, sepsis was a
serious problem and 3 of 6 cases that developed sepsis went on toDays
TEN
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Fig. 3. Total days of the hospital stay. Fifty-two cases of SJS and 35 cases of TEN were examined. The average numbers of days of the hospital stay were 20.8 days in SJS and 34.1 days
in TEN.
Table 1
Causative drugs of SJS and TEN.
Number of cases SJS TEN
Antibiotics 2 7
Penicillins 0 2
Carbapenems 1 4
Polypeptides (vancomycin) 1 1
NSAIDs and cold medicine 5 6
NSAIDs 3 5
Cold medicine 2 1
Anticonvulsants 13 4
Carmabazepine 4 1
Zonisamide 3 0
Phenobarbital 2 1
Lamotrigine 2 0
Alebiatin 1 0
Varpric acid 1 1
Gabapentin 0 1
Others 19 8y
Not determined 16 17
Total 53 42
y Including 3 cases of Omeprazole and 2 cases of Allopurinol.
Table 2
Organ involvements and complications in patients with SJS and TEN.
Number of cases (%) SJS TEN Total
Hepatitis 26 (50.0%) 15 (42.9%) 41 (47.1%)
Renal dysfunction 5 (9.6%) 8 (22.9%) 13 (14.9%)
Hemodialysis 0 1 1
Gastro-intestinal disordery 5 (9.6%) 4 (11.4%) 9 (10.3%)
Respiratory disorderz 2 (3.8%) 3 (8.6%) 5 (5.7%)
Encephalopathy 2 (3.8%) 5 (14.3%) 7 (8.0%)
Myocarditis 1 (1.9%) 1 (2.9%) 2 (2.3%)
Pneumoniax 4 (7.7%) 4 (11.4%) 8 (9.2%)
Sepsis 1 (1.9%) 6 (17.1%) 7 (8.0%)
Rhabdomyolysis 0 (0%) 1 (2.9%) 1 (1.1%)
DIC¶ 0 (0%) 3 (8.6%) 3 (3.4%)
y Gastro-intestinal disorder includes: diarrhea, intestinal bleeding, severe appe-
tite loss, perforation of intestine.
z Respiratory disorder includes: edema of trachea/larynx, respiratory failure.
x Pneumonia includes: Methicillin-resistance Staphylococcus aureus, Cytomega-
lovirus, Aspergillus, Candida.
¶ Disseminated intravenous coagulation.
Y. Yamane et al. / Allergology International 65 (2016) 74e81 77develop disseminated intravenous coagulation (DIC). Within the 3
cases, 2 cases died (described in deceased cases) and only 1 case
was survived. Alived case was 72-year-old man and he also had
hepatitis and severe renal dysfunction needed to receive hemodi-
alysis. A case of sepsis in SJS was 87-year-old woman who already
had pneumonia when she developed SJS and the treatment was
started 9 days after the development of SJS.Treatments
The major systemic treatments that were adopted in addition to
supportive carewere corticosteroids, IVIG, and plasmapheresis. The
treatments performed are shown in Table 3. All cases, except 2
cases of SJS and 1 case of TEN, were treated with corticosteroids
with or without other therapies. Prompt tapering of the steroid
dose was performed along with amelioration of symptoms. In SJS,
most cases (45 cases, 86.5%) were treated with corticosteroids
alone. Of the cases, 18 (34.6% of all SJS) were performed pulse
therapy (500e1000 mg/day of methylprednisolone for 3 days). On
the other hand, in TEN, steroid pulse therapy was performed in 31
cases (88.6%) of all cases. Less than half cases (14 cases, 40%) wereTable 3
Treatments in patients with SJS and TEN.
Treatments Number of cases
SJS TEN
Supportive care only 2 (3.8%) 0
Steroid therapy 45 (86.5%) 14 (40.0%)
Steroid pulse therapy 18 (34.6%) 12 (34.3%)
IVIG <2 g/kg 0 1 (2.9%)
Steroid therapy and IVIG 3 (5.8%) 8 (22.9%)
>2 g/kg 0 1
<2 g/kg 3 7
Steroid therapy and plasmapheresis 1 (1.9%) 10 (28.6%)
Steroid therapy, IVIG, and plasmapheresis 1 (1.9%) 2 (5.7%)
>2 g/kg 0 1
<2 g/kg 1 1
Total 52 cases 35 cases
IVIG, intravenous immunoglobulin.
u
m
sk
in
h
m
en
t
(%
)
C
lin
ic
al
co
u
rs
e
of
th
e
sk
in
le
si
on
Se
ve
re
co
m
p
lic
at
io
n
s
an
d
ca
u
se
of
d
ea
th
M
ax
im
u
m
d
os
es
of
co
rt
ic
os
te
ro
id
s
an
d
ot
h
er
th
er
ap
ie
s
SC
O
R
TE
N
Ti
m
e
to
d
ea
th
y
R
ec
ov
er
in
g
gr
ad
u
al
ly
R
es
p
ir
at
or
y
fa
ilu
re
PS
L
60
m
g/
d
ay
2
24
d
ay
s
N
o
ch
an
ge
Ed
em
a
of
tr
ac
h
ea
/l
ar
yn
x
R
h
ab
d
om
yo
ly
si
s
m
PS
L1
00
0
m
g/
d
ay

3
d
ay
s,
4
8
d
ay
s
R
ec
ov
er
in
g
gr
ad
u
al
ly
R
en
al
d
ys
fu
n
ct
io
n
Se
p
si
s,
D
IC
B
et
h
am
et
h
az
on
e
20
m
g/
d
ay
1
28
d
ay
s
R
ec
ov
er
ed
co
m
p
le
te
ly
Pe
rf
or
at
io
n
of
in
te
st
in
e,
Pn
eu
m
on
ia
,D
IC
m
PS
L
15
00
m
g/
d
ay

3
d
ay
s,
I
m
m
u
n
og
lo
bu
lin
20
g/
d
ay

3
d
ay
s
4
31
d
ay
s
R
ec
ov
er
ed
sl
ig
h
tl
y
Se
p
ti
c
sh
oc
k
PS
L
40
m
g/
d
ay
C
yA
35
m
g/
d
ay
Im
m
u
n
og
lo
bu
lin
20
g/
d
ay

3
d
ay
s
6
66
d
ay
s
N
o
ch
an
ge
C
on
vu
ls
io
n
,D
IC
,
Se
p
ti
c
sh
oc
k
In
te
st
in
al
bl
ee
d
in
g
m
PS
L1
00
0
m
g/
d
ay

3
d
ay
s
Pl
as
m
a
ex
ch
an
ge
2
d
ay
s
3
12
d
ay
s
A
;
N
SA
ID
s,
N
on
st
er
oi
d
al
an
ti
-i
n
ﬂ
am
m
at
or
y
d
ru
gs
.
Y. Yamane et al. / Allergology International 65 (2016) 74e8178treated with corticosteroids alone and among them 12 cases were
performed pulse therapy (500e1000 mg/day of methylpredniso-
lone for 3 days). The case treated without steroid was a 62-year-old
woman who was treated with IVIG (20 g/day for 2 days) alone,
because she had acquired Methicillin-resistance Staphylococcus
aureus (MRSA) pneumonia after the operation of acute aorta
dissection when she developed TEN. IVIG was highly effective in
this case and resulted in remarkable recovery from the TEN
eruption.
A combination treatment with IVIG and corticosteroids was
performed only in 3 cases of SJS. All 3 cases received less than 2 g/kg
(more than 1 g/kg) of immunoglobulin in total. Two of the 3 cases
were performed pulse therapy (500e1000 mg/day of methylpred-
nisolone for 3 days). One case of SJS was already being treated with
60 mg/day of prednisolone for systemic lupus erythematosus when
she developed SJS and she received the additional treatment of
double ﬁltration plasmapheresis (DFPP). Another SJS case was
treated with corticosteroids, IVIG, and plasmapheresis sequentially.
This case had developed SJS as a reaction to diaphenylsulfone (DDS)
taken for pemphigus foliaceus. To treat pemphigus foliaceus
together with SJS, DFPP was performed.
On the other hand, combination therapies were positively cho-
sen in TEN. Before starting IVIG or plasmapheresis, all cases were
performed steroid pulse therapy. Eight cases (22.9%) were treated
with the combination of IVIG (more than 1 g/kg) and corticoste-
roids, and 10 cases (28.6%) with the combination of plasmapheresis
and corticosteroids. Two cases (5.7%) were treated with steroid
pulse, IVIG, and plasmapheresis because of the progression of
symptoms. In contrast to SJS, 2 cases of TEN treated with IVIG after
2008 were administered with a total amount of more than 2 g/kg
immunoglobulin. All plasmapheresis treatments performed in TEN
were plasma exchange (PE) except for 1 case treated with steroid
pulse, IVIG (1 g/kg), and DFPP before 2006.Ta
b
le
4
D
ec
ea
se
d
ca
se
s
of
SJ
S
an
d
TE
N
.
C
as
e
N
o.
/a
ge
/s
ex
U
n
d
er
ly
in
g
d
is
ea
se
C
au
sa
ti
ve
d
ru
gs
In
d
ic
at
io
n
fo
r
d
ru
g
th
er
ap
y
M
ax
im
d
et
ac
SJ
S
1/
47
/M
N
ot
p
ar
ti
cu
la
r
N
ot
d
et
er
m
in
ed
(i
m
ip
en
em
/c
ila
st
at
in
so
d
iu
m
?
A
m
p
h
ot
er
ic
in
B
?)
M
al
ig
n
an
t
ly
m
p
h
om
a
10
%
>
TE
N
2/
39
/F
C
ae
sa
ro
to
m
y
N
ot
d
et
er
m
in
ed
(C
ef
d
it
re
n
p
iv
ox
il?
N
SA
ID
s?
)
C
ol
d
48
%
3/
79
/F
R
h
em
at
oi
d
ar
th
ri
ti
s,
H
ep
at
it
is
C
vi
ru
s
(H
C
V
)
p
os
it
iv
ec
h
ro
n
ic
h
ep
at
it
is
H
er
ba
l
m
ed
ic
in
e
C
ol
d
>
30
%
4/
74
/M
D
ia
be
te
s
m
el
lit
u
s,
R
en
al
fa
ilu
re
,A
st
h
m
a,
H
yp
er
te
n
si
on
,
A
n
gi
n
a
p
et
or
is
m
er
op
en
em
?
A
cu
te
ao
rt
a
d
is
so
ci
at
io
n
40
%
5/
54
/M
C
h
ro
n
ic
n
ep
h
ri
ti
s
N
ot
d
et
er
m
in
ed
M
u
lt
ip
le
m
ye
lo
m
a
95
%
6/
71
/F
D
ia
be
te
s
m
el
lit
u
s,
R
en
al
fa
ilu
re
(u
n
d
er
h
em
od
ia
ly
si
s)
,
B
u
llo
u
s
p
em
p
h
go
id
N
ot
d
et
er
m
in
ed
(P
ip
er
ac
ill
in
So
d
iu
m
?
C
ef
tr
ia
xo
n
e
So
d
iu
m
H
yd
ra
te
?)
fe
ve
r
of
u
n
kn
ow
n
or
ig
in
10
%
m
PS
L,
M
et
h
yl
p
re
d
n
is
ol
on
e;
D
IC
,D
is
se
m
in
at
ed
In
tr
av
en
ou
s
C
oa
gu
la
ti
on
;
PS
L,
Pr
ed
n
is
ol
on
e;
C
yA
,C
yc
lo
sp
or
in
y
Ti
m
e
be
tw
ee
n
th
e
on
se
t
of
er
u
p
ti
on
an
d
d
ea
th
.Mortality, deceased cases, and sequelae
Total mortality was 6.9%. One case of SJS (mortality rate, 1.9%)
and 5 cases of TEN (mortality rate, 14.3%) died. The average
SCORTEN score was 2.34, thus the predicted mortality rate was
25.3% (8.9 cases) in TEN.
A summary of the deceased cases is shown in Table 4. The
deceased SJS case was a 47-year-old man. He developed an acute
respiratory disorder after the eruption had begun to show signs of
recovery. The death was doubted to have been caused by the ma-
lignant lymphoma that was the primary disease. As for TEN, the
ages of the deceased cases varied from 39 to 79 years, with an
average age of 63.4 years. All cases were treated with corticoste-
roids and 3 of themwere treated with combination therapy of IVIG
(<2 g/kg) or PE. Sepsis and DIC accompanied TEN in 3 cases. A 79-
year-old woman caused sepsis and DIC after developing severe
renal dysfunction. In this case, the dose of the administered corti-
costeroids was increased gradually from prednisolone 30mg/day to
100 mg/day and ﬁnally changed to betamethasone 20 mg/day. A
54-year-old man case already had showed very severe general
condition at the start of the treatment of TEN, which made it
difﬁcult to administer the corticosteroids at the high-dose, and
ended to septic shock. A 71-year-old woman had developed TEN
during the treatment of fever of unknown origin, which could be
suspicious of some kind of systemic infection hidden and led to
septic shock and DIC.
No cases showed severe sequelae in either SJS or TEN. Only 1
case of TEN, a 17-year-old man, showed a loss of ﬁngernails.
Although many reports indicate that eye complications often result
in severe eye sequelae, no cases in this study showed eye sequelae.
Y. Yamane et al. / Allergology International 65 (2016) 74e81 79Comparison of treatment modalities used and mortality rates
between 2000e2006 and 2007e2013 in TEN
After plasmapheresis for SJS/TEN became eligible for coverage
by health insurance in 2006, the available options of treatment
modalities have been changing in TEN. Therefore, we separated the
cases by the date of each 7 years before and after this change
(2000e2006 and 2007e2013) and compared the treatment mo-
dalities used and the mortality rates in these 2 periods. From 2000
to 2006, 22 cases of SJS and 17 cases of TEN were evaluated. From
2007 to 2013, 30 cases of SJS and 18 cases of TEN were evaluated.
Although steroid pulse therapy and the combination of IVIG ther-
apy (<2 g/kg) with corticosteroid therapy were the mainstream
until 2006, the frequency of cases treated with the combination of
plasmapheresis and corticosteroid therapy increased remarkably
after 2007 (shown in Fig. 4).
The mortality rates showed a remarkable decrease after 2007,
compared with 2000e2006, from 4.5% to 0.0% in SJS and from
23.5% to 5.6% in TEN, although the average SCORTEN scores were
somewhat elevated after 2007 (2.18 in 2000e2006 and 2.50 in
2007e2013). We compared the predicted mortality rate of TEN
cases with the actual rate. Only a little difference was shown in
2000e2006; the predicted rate was 23.9% (4.1 cases) and the actual
rate was 23.5% (4 cases). However, it showed a relatively large gap
in 2007e2013; the predicted rate was 26.5% (4.8 cases) and the
actual rate was 5.6% (1 case). Furthermore, when comparing the
average SCORTEN score of the non-deceased cases between the 2
periods, it showed a relatively large increase from 1.69 to 2.47.
Discussion
SJS and TEN are rare but life-threatening disorders. The mor-
tality rates for these conditions were recently reported to be 34% at
1 year for SJS/TEN in Europe18 and 3% and 19% for SJS and TEN,
respectively, in Japan.19 Recent studies have revealed new details
about the apoptotic pathways of keratinocytes and immunological
changes that are related to adverse drug reactions in these dis-
eases.8,20e23 In addition to the direct cytotoxicity by the cytotoxic T
cells (CTLs), several soluble factors such as tumor necrosis factor-a,
nitric oxide, soluble Fas ligand (sFasL), granulysin, annexin A1 are
now considered to mediate keratinocyte apoptosis. Abe et al. re-
ported that peripheral blood mononuclear cells (PBMCs) from SJS/
TEN patients secrete sFasL on stimulation with the causal drug. In
addition, they demonstrated that patients sera induce apoptosis in
cultured keratinocytes, indicating that sFasL produced by PMBCs
may contribute to the pathogenesis of SJS/TEN.21 Chung et al.0
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Fig. 4. Changes in the treatments used between 2000e2006 and 2007e2013 in TEN. A, Stero
plasmapheresis; E, Steroid, IVIG, and plasmapheresis, F, IVIG (without corticosteroids). IVIG, i
(2007e2013) were evaluated.clariﬁed that granulysin produced by CTLs or natural killer cells
concentrations in the blister ﬂuids of SJS/TEN skin lesions were two
to four orders of magnitude higher than perforin, granzyme B or
sFasL concentrations, and depleting granulysin reduced the cyto-
toxicity of the keratinocytes. Furthermore, they showed that in-
jection of granulysin into mouse skin resulted in features
mimicking SJS-TEN.22 Recently Saito et al. revealed the contribution
of annexin A1 in keratinocyte necroptosis of SJS/TEN. Depletion of
annexin A1 by a speciﬁc antibody diminished supernatant cyto-
toxicity. SJS/TEN keratinocytes expressed abundant formyl peptide
receptor 1, the receptor for annexin A1, whereas control keratino-
cytes did not. They also showed that inhibition of necroptosis
completely prevented SJS/TEN-like responses in a mouse model of
SJS/TEN.23
There is no established therapy for SJS/TEN, although many
treatment modalities including corticosteroid, plasmapheresis, and
IVIG have been used. The challenge remains that it is difﬁcult to
assess the efﬁcacies of treatments for such serious and rare disor-
ders in a large clinical randomized controlled trial (RCT).
In this study, we presented the current clinical characteristics
and treatments of SJS and TEN in 87 patients treated in our 2
hospitals to evaluate the usefulness of these treatments
retrospectively.
The ages of patients with SJS and TEN were widely distributed
from young to older. The major causative drugs were antibiotics,
anticonvulsants, NSAIDs, and cold medicines. The predominance of
these drugs in causing the diseases seems to have been unchanged
since Aihara et al. analyzed 269 cases of SJS and 287 cases of TEN
that were reported from 1981 to 1997 in Japan.24 However, in our
study, anticonvulsants were more frequently the causative drugs
than has been previously reported in SJS. This might be related to
the fact that in recent years, anticonvulsants have been used not
only for convulsions but also for other diseases, such as neurogenic
pain and bipolar disorder.
In addition to the severe skin symptoms, many organ in-
volvements were observed. The organs most commonly involved
were liver and kidneys. However, while less common than hepatitis
and renal dysfunction, respiratory and gastro-intestinal disorders
were severe conditions often resulting in fatality. In addition to
multi-organ involvement, another major problem in the clinical
course was secondary infections, especially sepsis.
As for treatments, systemic corticosteroid therapy was mainly
used both in SJS and TEN in Japan.25 The use of corticosteroids is
based on the idea that corticosteroids effectively suppress an
excessive immune response. While their use is still controver-
sial,18,26 recent studies have suggested them to be a valid treatmentA B C D E F
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Y. Yamane et al. / Allergology International 65 (2016) 74e8180modality for SJS/TENS.6,7,27 Tripathi et al. reviewed 67 patients, and
only 1 patient died of causes not related to steroid therapy.6 They
recommended the prompt use of high-dose systemic corticoste-
roids for a relatively brief period for the treatment of SJS. Hirahara
et al. evaluated 8 patients treated with methylprednisolone pulse.
They reported no deaths among these patients, whereas the pre-
dicted mortality was 1.6 deaths according to the SCORTEN scoring
system (the mean SCORTEN score was 2.1).27
In the present study, corticosteroids were used to treat all pa-
tients except 3, and many of them were treated with steroid pulse
therapy. The mortality was 6 deaths (6.9%) and all deceased cases
were treated with steroids. However, this mortality was much
lower than the predicted mortality (8.9 deaths, 25.3% in TEN) ac-
cording to the SCORTEN scoring system. As we mentioned in detail
about the 3 deceased TEN cases with sepsis, 2 cases received
administration of corticosteroids in inadequate dose. Another 1
case with fever of unknown origin was suspected to have had un-
derlying systemic infection. Although it is undeniable that corti-
costeroids may facilitate secondary infection, prompt tapering of
the dose after amelioration of SJS/TENS symptoms was considered
to reduce the risk of fatal adverse effects of the systemic
corticosteroids.
In addition to the steroid therapy, plasmapheresis (mostly PE)
and IVIG were performed in severe TEN cases. Plasmapheresis
has been reported to be effective in several studies of TEN after
the middle of the 1980s.13,14,28,29 The mechanism of its effec-
tiveness remains speculative, but most likely involves the
removal of drugs and drug metabolites, soluble Fas ligand, and
chemical mediators from the blood circulation. In our study, 14
patients including 12 TEN with average SCORTEN score 2.58
(predicted mortality 3.68 deaths, 30.6%) were treated with
plasmapheresis and only one TEN patient died (mortality rate
7.4%). This data might show the possibility that plasmapheresis is
useful modality in the treatment of refractory TEN after starting
steroid therapy.
IVIG therapy with an acute TEN patient was ﬁrst reported by
Viard et al. in 1998.8 After that report, many studies have revealed
the effectiveness of IVIG therapy. The mechanisms are suspected to
involve the inhibition of Fas-mediated keratinocyte death by
naturally occurring Fas-blocking antibodies in the administered
immunoglobulins and the inhibition of inﬂammatory cytokines. In
addition, it has been thought that IVIG works through mechanisms
of inhibition of inﬂammatory cells and modulation of immune
function in inﬂammatory diseases.30 However, the effect of IVIG is
still controversial.31,32 In 2006, French et al. summarized the clinical
studies reported and suggested that the use of more than 2 g/kg of
body weight of intravenous immunoglobulin is beneﬁcial on the
mortality associated with TEN.9 Barron et al.33 conducted a meta-
analysis with meta-regression of 13 observational studies con-
ducted during the period of 1966e2011 to assess IVIG in the
treatment of SJS/TEN based on the SCORTEN scoring system. They
showed that IVIG at doses of 2 g or more/kg appears to signiﬁcantly
decrease mortality. Chen et al.34 also recommended the use of IVIG
with total doses of more than 2 g/kg for the treatment of SJS/TEN.
They reported that early application of steroids provided beneﬁcial
effects, and that combination therapy with steroids and IVIG
showed better therapeutic effects than did steroids alone. In our
study, 15 patients including 11 TEN with average SCORTEN score
2.09 (predicted mortality 2.59 deaths, 23.6%) were treated with
IVIG and the mortality rate was 13.3% (2 deaths). The total amount
administered was less than 2 g/kg in 13 cases, including 2 deceased
cases administered with a total of 60 g each of IVIG (SCORTEN
scores 4 and 6, respectively). IVIG was administered in combination
with corticosteroids except in 1 case of TEN with underlying
infection. In 2 of these cases with TEN, plasmapheresis wasadditionally performed after IVIG administration because it had not
been effective enough. In addition, since only 2 patients were
treated with IVIG at a dose of more than 2 g/kg in the study period,
we are not able to discuss the efﬁcacy of IVIG in terms of dose-
dependence. Taken together, it is difﬁcult to evaluate the addi-
tional effects of IVIG accurately from these data.
In the comparison of the data between 2000e2006 and
2007e2013, it was shown that the average SCORTEN score of the
non-deceased cases rose from 1.69 to 2.47 after 2007 and the
mortality rate fell from 23.5% to 5.6% in TEN. These changes seem to
owe to the alterations in the treatments predominantly used for
TEN between these 2 time periods. More cases were treated with
the combination of corticosteroid therapy and PE at the early stage
of each disease after 2007, because plasmapheresis as a treatment
for SJS and TEN became eligible for coverage by health insurance in
April 2006 in Japan. In addition, IVIG therapy at a dose of more than
2 g/kg was started in these latter years. In these patients, each
treatment was started immediately one after another, when the
initial treatment was thought not to be effective enough. From
these facts, it is likely that treatments based on steroid therapy in
combinationwith plasmapheresis and possibly IVIG are effective in
SJS and TEN. The major factors inﬂuencing the efﬁcacy of combi-
nation therapy seem to be the dose of steroids and timing of start of
each treatment.
In conclusion, improvement of mortality of SJS/TEN was
observed in 2007e2013, compared with 2000e2006. Treatment
with steroids in combination with plasmapheresis and/or IVIG
more than 2 g/kg seems to have contributed to this improvement.
To inform the development of guidance as to the optimum treat-
ment regimen, RCT studies are required. However, it is difﬁcult to
perform RCT for these diseases because of ethical problems.Acknowledgment
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